Nanotechnology-Based Drug Delivery Company to Announce Breakthroughs
(Nanowerk News) PharmaNova, a leader in nanotechnology-based Drug Delivery Systems, is due to exhibit at the 2009 annual meeting of the American Association of Pharmaceutical Scientists (AAPS) scheduled in Los Angeles, CA, from November 8 - 12.
The Company will announce new technology breakthroughs in discussions with visitors to the exhibit. The meeting will be at Los Angeles Convention Center and the booth location is 2451.
NovaSperse(SM) technology is focused on the formation of stable amorphous nanoparticles with excellent reproducibility. This technology is being applied to both New Product Opportunities (NPOs) and Client Sponsored Projects (CSPs).
PharmaNova’s proprietary NovaSperse technology offers proactive control of nanoparticle characteristics and is tailored to the unique chemistry of individual active pharmaceutical ingredients (APIs). PharmaNova’s scientists are actively advancing the NovaSperse(SM) technology platform towards attaining a leadership position among nanotechnology-enabled drug delivery companies.
A nanometer is one-billionth of a meter; a human hair is roughly 100,000 nanometers wide; a human fingernail grows 1 nanometer every second; a sheet of paper is about 100,000 nanometers thick.
About PharmaNova
PharmaNova Inc. is a privately held, specialty pharmaceutical company founded on the re-positioning and enhancement of known drugs using its proprietary NovaSperse(SM) nanoparticle technology platform and other complementary drug delivery and formulation technologies. We address low-risk, fast-to-market products in areas of clear medical need and generate revenue from partnering and licensing strategies with commercialization partners worldwide. PharmaNova also provides contractual services for the NovaSperse(SM)-based formulation of client-owned APIs. PharmaNova’s pipeline includes a (partnered) non-hormonal treatment for menopausal hot flashes and topical anti-infective and ophthalmic new product opportunities. PharmaNova and Altacor of Cambridge, England, have formed a strategic alliance to develop and commercialize a series of new prescription ophthalmic medical products based on PharmaNova’s proprietary NovaSperse(SM) nanoparticle technology.
Printer-friendly
E-mail this article
Daily News Email Digest
News Feeds
Join us on Facebook
Follow us on Twitter
